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Sequence variations in the binding sites of influenza A proteins are known to limit the effectiveness of 
current antiviral drugs. Clinically this leads to increased rates of virus transmission and pathogenicity. 
Potential influenza A inhibitors are continually being discovered as a result of high-throughput cell 
based screening studies, while the application of computational tools to aid drug discovery has further 
increased the number of predicted inhibitors reported. This review brings together the aspects that 
relate to the identification of influenza A drug target sites and the findings from recent antiviral drug 
discovery strategies. 
 




Every year the Influenza A virus infects humans worldwide with varying levels of severity. Since the 
worst human outbreak known as the H1N1 Spanish flu was reported in 1918 which killed 
approximately 50 million people [1], major pandemics with significant mortality rates have continued 
to occur [2,3]. Besides human to human transmission, this zoonotic virus has the potential to be 
transmitted between a range of hosts such as birds and pigs, amongst other animals. Such cross-
species transmission, in particular of avian origin can lead to the formation of re-assortant viruses 
through mixing of genetic segments and has shown to confer an increase in pathogenicity to the 
human population [4]. The virus particle consists of eight RNA segments in complex with proteins 
required for the initial stages of replication that are surrounded by a protein shell and a lipid bilayer. 
Various proteins traverse the lipid bilayer, such as haemagglutinin (HA), neuraminidase (NA) and the 
matrix protein 2 (M2) proton channel.  The complex replication cycle requires several functional 
proteins to enable attachment, genome replication and release of the virus from infected cells [5]. 
Currently up to 17 proteins have been discovered; many of which are produced from a single RNA 
segment. However, not all of these proteins contribute to infection, nor are they found to be present in 
all virus subtypes [6]. Subtypes are classified according to antigenic properties of the HA and NA 
surface proteins as HxNy. The HA glycoprotein is also the major virulence determinant and stimulates 
production of neutralising antibodies at the start of the infectious cycle. A schematic overview of the 

















Figure 1. A brief overview of the Influenza A infectious virus life cycle including the major proteins 
involved. 
In addition to genome re-assortments, replication errors by the polymerase also leads to genomic 
diversity and rapid evolution of the genome which can impair constituent protein functions, or 
alternatively enable proteins with additional functions [5,7]. Furthermore, the annual trivalent vaccine 
formulated against the expected circulating strains does not provide extensive protection against the 
virus. In February 2015, the high rate of evolution of the virus was exemplified by a mutation in the 
circulating H3N2 vaccine strain, which severely impacted the effectiveness of the vaccine [8]. 
Consequently, once infection is established in a host, antiviral drugs are the only treatment options 
available.  
 
Current influenza antivirals and documented resistance 
 
In the United Kingdom there are currently two classes of antiviral drugs licensed for treatment and 
prophylaxis of influenza A based on their method of action. The neuraminidase inhibitors (NAIs) 
Oseltamivir and Zanamivir developed in the 1990’s function to block the neuraminidase active site, 
preventing enzymatic cleavage of sialic acid residues on the surface of infected cells to stop the virus 
from spreading [9]. The drugs Laninamivir and Peramivir also act as NAIs and have recently been 
approved for use in certain countries only. Each of these drugs has different routes of administration; 
with Oseltamivir taken orally, Zanamivir taken through inhalation and Laninamivir and Peramivir 
taken intravenously. The M2 inhibitors (adamantanes) are a much older class of orally administered 
drugs developed in the 1960’s and function to obstruct the M2 proton channel, preventing the 
uncoating and entry of viral particles into cells [10]. Additionally, a compound known as Arbidol that 
inhibits haemaglutinin membrane fusion in vitro is licensed in Russia and China [11], and the novel 
antiviral compound Favipiravir which acts as a purine analog to target the RNA polymerase is 
currently in late stage clinical trials in the USA [12]. 
 
However, since most of these drugs were approved, there has been increasing reports of drug 
resistance against seasonal and pandemic strains [13]. The mechanism of resistance relates to amino 
acid changes (single point mutations) near or within the binding sites of functional regions in viral 
proteins. These mutations may confer high levels of antiviral resistance and can emerge in all 
influenza strains worldwide. Such examples include pandemic H1N1 strains harbouring the Histidine 
to Tyrosine substitution at position 274 (H274Y). This change alters the NA catalytic site 
conformation resulting in reduced drug binding affinity corresponding to antiviral treatment failure 
[13,14]. Similarly, the affinity of drug binding is reduced by the S31N substitution in the M2 
transmembrane domain [15], and due to widespread resistance, adamantanes are no longer 
recommended for antiviral treatment by the Centres for Disease Control and Prevention. Several other 
amino acid mutations in functional or framework residues of the neuraminidase and M2 proteins have 
been found which also confer a resistant phenotype [16,17]. The clinical use and choice of influenza 
antivirals is therefore complicated by resistance issues and drug induced selective pressures, which 
highlights the requirement to discover new targets and novel antiviral agents to reduce replication and 
combat infection. Additionally, due to lower rates of evolution based on sequence and structure 
analysis, there is increasing focus on investigating internal proteins as target sites for antiviral drugs 
[18]. In order to avoid a fruitless arms race between drug discovery and virus evolution, it has been 
suggested that antiviral drug discovery efforts should be focussed on the most evolutionary conserved 
binding sites [19], even if this places restrictions on the drug target sites available.  
 
 
The essential internal proteins required for virus replication  
 
The RNA dependent RNA polymerase enzyme involving the acid polymerase (PA), basic polymerase 
1 (PB1) and basic polymerase 2 (PB2) are the largest proteins which form a heterotrimeric complex in 
the virion to synthesize mRNA templates for protein synthesis and cRNA for further genome 
transcription. Each subunit has a distinct function; the PA contains a N-terminal endonuclease domain 
to cleave capped host mRNA, the N-terminus of PB1 binds to PA to regulate transcriptase activity and 
mRNA chain elongation, and PB2 binds to the 5’ methylated cap of host cell mRNA to generate 
primers for transcription [20,21]. Sequence analysis have proven that the polymerase is highly 
conserved amongst functional regions of different strains and contains multiple sites for potential drug 
discovery [7,18,22]. Together with viral RNA, the polymerase subunits also associate with the 
nucleoprotein (NP) to form ribonucleoprotein (RNP) complexes, which act as a mediator between the 
virus and host cell. The NP also facilitates RNA synthesis, controls RNP trafficking and regulates 
polymerase activity and packaging of the genome, as well as performing many other functions [23]. 
The NP is also the most abundant internal protein, consisting of a body (N-terminal), head, and tail 
(C-terminal) loop domain and is also considered to be an attractive antiviral target [19,24]. Structures 




Figure 2. Structures of the internal influenza A proteins encoded by the RNA genome segments. The 
NP (PDB 2Q06), NS1 (PDB 3F5T) and NEP (PDB 1PD3) are coloured with reverse rainbow gradient 
from the N-terminal in red to C-terminal in blue. The polymerase subunits are shown as a trimer 
complex (PA, red; PB1, green; PB2, blue (PDB 4WSB)).  This figure was made using EzMol [25]. 
 
 
Modelling of protein structures  
 
Unlike the surface proteins HA, NA and M2 for which there are a number of solved structures in the 
Protein Data Bank (PDB), there is currently limited availability of full length crystal structures for 
some of the internal influenza A proteins. Various modelling tools for reliable protein structure 
prediction have been developed [26–28] and can be used to account for the lack of 3D structural 
information available. However, there is a low template coverage for some of the influenza proteins 
such as NS2, PB1 and PB2 using homology modelling methods [18]. Accurately constructed models 
and experimentally determined structures can aid with characterisation of binding sites, understanding 
the effects of mutations as well as permit in silico drug discovery studies. One example is a receptor 
based virtual screening study which specifically targeted the CPSF30 binding pocket on the non-
structural protein (NS1) effector domain. From a library of ~200,000 compounds, the docking results 
revealed compounds with predicted binding affinities up to -10.0kcal/mol, but whether these 
compounds can reduce virus replication is yet to be elucidated [29]. Computational methods 
combining sequence and structural information have also been used to identify new ligand binding 
sites in highly conserved regions of internal proteins such as NS1, NEP and NP [30,31]. Furthermore, 
proteins which are flexible and can adopt different conformations to influence the function and ligand 
binding activity can also be analysed with molecular dynamics simulation as exemplified by studies 
of the NP [32], M2 [17] and NA [33,34] proteins.   
 
 
Recent approaches to discover virus replication inhibitors 
 
In recent years, a number of high throughput cell based screening assays have been performed, which 
have lead to discoveries of potential inhibitors of various subtypes. Several NS1 antagonists that 
reduce virus replication have been identified in different studies reviewed for example by Engel [35]. 
This includes the inhibitor molecule known as JJ3297 identified in 2010, which has also been tested in 
virus quantification assays. Results showed that JJ3297 was able to increase production of IFN 
mRNA; a mechanism which NS1 is well known to antagonise, and reduced influenza A replication by 
at least three orders of magnitude. However, the precise mechanism of action and binding regions of 
JJ3297 to NS1 have not been identified [36]. The molecule was synthesized based on a previously 
identified NS1 inhibitor NSC125044 [37]. Similarly, a novel small molecule inhibitor ASN2 that 
targets the viral polymerase and inhibits influenza A replication has been discovered from a high-
throughput cell screening assay. The suggested target of ASN2 is the Y499 residue of the PB1 protein 
resulting in impaired polymerase function and consequently reduced expression of NS1 [38]. In 2011, 
the inhibitor Nucleozin was identified from a virtual screening study and has been found to target the 
nucleoprotein [39,40] or the viral RNP complex. Inhibitory effects on virus replication have been 
shown in vitro as a result of NP aggregation [38].  In 2013, the small molecule Naproxen was also 
initially identified by virtual screening, followed by molecular dynamics, and verified by in vitro 
antiviral tests to show reduced viral titres. The binding region of Naproxen is reported to be at the 
RNA binding groove of NP consisting of the aromatic residues, Y148 and F489 [41]. Most recently, 
the compound RK424 identified in July 2015 from a compound library screening was also found to 
target the NP/RNP complex and reduced virus replication of several strains including H1N1, H5N1 
and H7N9 in cell based replication assays. Molecular docking against a H1N1 NP crystal structure 
was used for further analysis to determine how RK424 inhibits NP function, and results showed that 




The influenza A virus undoubtedly remains a threat to public health. The ongoing reports of antiviral 
drug resistance and circulation of resistant subtypes have emphasised the fact that alternative 
antivirals with long term effectiveness should be developed. Finding inhibitors to accommodate the 
diversity of the virus genome and unpredictable rate of evolution continues to present challenges in 
drug discovery. However, with increased understanding of virus biology and the application of 
computational methods together with experimental investigations, the field of influenza drug 
discovery is rapidly progressing. Molecules that could inhibit virus replication at stages other than 
entry and release by targeting internal proteins such as the polymerase, nucleoprotein and non-
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